Despite the announcement of the Human Genome Project in 2003 and the decipherment of protein function for the entire genome in 2022, few new therapeutics are on the market and many patients suffering from rare and invasive genetic diseases are waiting for scientific breakthroughs.

GenesisGaia aims to use artificial intelligence to reduce R&D bottlenecks and market slowdowns to bring new medicines to patients faster. Some experts also predict that more than 30% of new drugs will be systematically discovered using generative AI technology by 2025, leading to faster decision-making and reduced R&D costs. (Gardner, 2021)

GenesisGaia is an innovative life science platform that unifies over 31 million data points from various open source public databases about genes, variants, proteins, compounds, papers and clinical trials, all of which are the largest commercially available genetic databases in Japan (over 400,000 genomes enriched with phenotypic data) compiled by Genesis Healthcare over the last 20 years.

Genesis Healthcare will continue to strive to provide a life science research and development platform (ONE-STOP Life Science R&D Platform) that utilizes genome data .